1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024

EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024

Summary

Sjögren’s syndrome (SS) is a chronic systemic autoimmune disease characterized by chronic inflammation of the exocrine glands and is one of the three most common autoimmune diseases in the US. Due to the lack of validated and universally accepted diagnostic criteria for diagnosing SS, a large variation can be seen in the rates of this disease. The three most commonly utilized diagnostic criteria for SS include the Copenhagen criteria, the European classification criteria, and the International Collaborative Clinical Alliances Cohort (SICCA) criteria. The European classification criteria, which were revised by the American-European Consensus Group (AECG), are currently the most widely used diagnostic criteria. Even though no cure currently exists for SS, treatments are used to manage the symptoms and prevent further complications. These might include the use of salivary substitutes and artificial tears, or in the case of secondary SS, treatment of the underlying disease.

GlobalData epidemiologists estimate that within the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, Japan), as shown in Figure 1, the diagnosed prevalent cases of SS will increase from 3,210,390 cases in 2014 to 3,533,298 cases in 2024, at an Annual Growth Rate (AGR) of 1.01% over the forecast period. Throughout the forecast period, the US will have the highest number of diagnosed prevalent cases of SS in the 7MM. Similarly, the diagnosed prevalent cases of primary Sjögren’s syndrome (pSS) will increase from 2,161,973 cases in 2014 to 2,384,551 cases in 2024, while the diagnosed prevalent cases of secondary Sjögren’s syndrome (sSS) will increase from 1,048,417 cases in 2014 to 1,148,874 cases in 2024. During the forecast period, the proportion of ocular manifestations in the diagnosed prevalent cases of SS will range from a low of 87.00% in the UK and the US to a high of 98.00% in Italy. Similarly, approximately, 93.00-96.00% of prevalent SS cases will experience oral symptoms during the forecast period.

Scope

- The Sjögren’s Syndrome (SS) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for SS, which includes both primary Sjögren’s syndrome (pSS) and secondary Sjögren’s syndrome (sSS), in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of pSS, segmented by sex and age (from 18-19 years, then in 10-year age groups), diagnosed prevalent cases of sSS as well as SS and cases of ocular and oral manifestations in SS, in these markets.
- The SS epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The SS EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global SS market.
- Quantify patient populations in the global SS market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for SS therapeutics in each of the markets covered.

Table Of Contents

EpiCast Report: Sjögren’s Syndrome - Epidemiology Forecast to 2024
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.3 Global Trends 12
3.3.1 7MM Diagnosed Prevalent Cases 14
3.3.2 5EU Diagnosed Prevalent Cases 15
3.3.3 Japan Diagnosed Prevalent Cases 15
3.4 Forecast Methodology 15
3.4.1 Sources Used 19
3.4.2 Sources Not Used 21
3.4.3 Forecast Assumptions and Methods 22
3.5 Epidemiological Forecast for SS (2014-2024) 26
3.5.1 Diagnosed Prevalent Cases of SS 26
3.5.2 Age-Specific Diagnosed Prevalent Cases of pSS 32
3.5.3 Sex-Specific Diagnosed Prevalent Cases of pSS 34
3.5.4 Age-Standardized Diagnosed Prevalence of pSS 36
3.5.5 Ocular and Oral Manifestations 38
3.6 Discussion 39
3.6.1 Epidemiological Forecast Insight 39
3.6.2 Limitations of the Analysis 41
3.6.3 Strengths of the Analysis 41
4 Appendix 43
4.1 Bibliography 43
4.2 About the Authors 47
4.2.1 Epidemiologists 47
4.2.2 Reviewers 47
4.2.3 Global Director of Therapy Analysis and Epidemiology 49
4.2.4 Global Head of Healthcare 49
4.3 About GlobalData 50
4.4 About EpiCast 50
4.5 Disclaimer 51

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for SS 11
Table 2: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of pSS 16
Table 3: 7MM, Sources Used to Forecast the Oral and Ocular Manifestations of SS 17
Table 4: 7MM, Sources Not Used in the Epidemiological Analysis of SS 22
Table 5: Diagnosed Prevalent Cases of SS, Age ?18 Years, Both Sexes, N, 2014-2024 31
Table 6: 7MM, Age-Specific Diagnosed Prevalent Cases of pSS, Age ?18 Years, Both Sexes, N, 2014 33
Table 7: 7MM, Sex-Specific Diagnosed prevalent Cases of pSS, Age ?18 Years, N, 2014 35

1.2 List of Figures
Figure 1: Diagnosed Prevalence Rate of SS in the 7MM, 2014 14
Figure 2: Case Flow Map for pSS: US, Germany, Italy, UK, and Japan 18
Figure 3: Case Flow Map for pSS: France and Spain 19
Figure 4: 7MM, Diagnosed Prevalent Cases of pSS, Age ?18 Years, Both Sexes, N, Selected Years, 2014-2024 27
Figure 5: 7MM, Diagnosed Prevalent Cases of sSS, Age ?18 Years, Both Sexes, N, Selected Years, 2014-2024 29
Figure 6: 7MM Diagnosed Prevalent Cases of SS, Age ?18 Years, Both Sexes, N, Selected Years, 2014-2024 32
Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of pSS, Age ?18 Years, Both Sexes, N, 2014 34
Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of pSS, Age ?18 Years, N, 2014 36
Figure 9: 7MM, Age-Standardized Diagnosed Prevalence of pSS, Age ?18 Years , 2014 37
Figure 10: 7MM, Ocular and Oral Manifestations of SS in the Diagnosed Prevalent Cases of SS, Age ?18 Years , 2014 39

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Epiomic Epidemiology Series: Rheumatoid Arthritis Forecast in 17 Major Markets 2016-2026

Epiomic Epidemiology Series: Rheumatoid Arthritis Forecast in 17 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Rheumatoid Arthritis in 17 Major Markets Rheumatoid arthritis (RA) is classified as an autoimmune disease and occurs when the immune ...

Epiomic Epidemiology Series: Traumatic Brain Injury Forecast in 21 Major Markets 2016-2026

Epiomic Epidemiology Series: Traumatic Brain Injury Forecast in 21 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Traumatic Brain Injury in 21 Major Markets Traumatic brain injury (TBI) or acquired brain injury is a non-specific term describing ...

Epiomic Epidemiology Series: Lower Back Pain and Sciatica Forecast in 9 Major Markets 2016-2026

Epiomic Epidemiology Series: Lower Back Pain and Sciatica Forecast in 9 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • October 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Lower Back Pain and Sciatica in 9 Major Markets Low back pain (LBP) is defined as experiencing musculoskeletal pain, muscle tension, ...


Download Unlimited Documents from Trusted Public Sources

Antidepressant Market and Bipolar Disorder Statistics in the UK

  • January 2017
    9 pages
  • Antidepressant  

    Bipolar Disorde...  

    Depression  

  • United Kingdom  

View report >

Stroke Statistics in the Netherlands

  • January 2017
    19 pages
  • Stroke  

  • Netherlands  

    Europe  

View report >

Obesity Statistics and Diabetes Statistics in Europe

  • January 2017
    48 pages
  • Obesity  

    Diabetes  

    Hypertension  

  • Europe  

View report >

Diabetes Statistics

23 hours ago

Related Market Segments :

Epidemiology

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.